Engineering and Characterization of a Long-Half-Life Relaxin Receptor RXFP1 Agonist
Molecular Pharmaceutics · 2024
DOI: 10.1021/acs.molpharmaceut.4c00368 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Sarah C Erlandson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts 02115, United State…. Hauptthemen laut MEDLINE: Receptors, G-Protein-Coupled, Relaxin, Receptors, Peptide. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NHLBI NIH HHS, Damon Runyon Cancer Research Foundation.
Abstract (Originalsprache)
Relaxin-2 is a peptide hormone with important roles in human cardiovascular and reproductive biology. Its ability to activate cellular responses such as vasodilation, angiogenesis, and anti-inflammatory and antifibrotic effects has led to significant interest in using relaxin-2 as a therapeutic for heart failure and several fibrotic conditions. However, recombinant relaxin-2 has a very short serum half-life, limiting its clinical applications. Here, we present protein engineering efforts targeting the relaxin-2 hormone in order to increase its serum half-life while maintaining its ability to activate the G protein-coupled receptor RXFP1. To achieve this, we optimized a fusion between relaxin-2 and an antibody Fc fragment, generating a version of the hormone with a circulating half-life of around 3 to 5 days in mice while retaining potent agonist activity at the RXFP1 receptor both in vitro and in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts 02115, United States.
- Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, United States.
- Department of Cell Biology, Duke University Medical Center, Durham, North Carolina 27710, United States.
ORCID-Profile: Haoran Jiang, Howard A Rockman, Andrew C Kruse
Förderung
- NIGMS NIH HHS
- NHLBI NIH HHS
- Damon Runyon Cancer Research Foundation
- National Heart, Lung, and Blood Institute
- Harvard Medical School
- National Institute of General Medical Sciences
Zitieren
APA
Erlandson, S. C., Wang, J., Jiang, H., Osei-Owusu, J., Rockman, H. A., & Kruse, A. C. (2024). Engineering and Characterization of a Long-Half-Life Relaxin Receptor RXFP1 Agonist. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00368
Vancouver
Erlandson SC, Wang J, Jiang H, Osei-Owusu J, Rockman HA, Kruse AC. Engineering and Characterization of a Long-Half-Life Relaxin Receptor RXFP1 Agonist. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00368
BibTeX
@article{Erlandson2024,
author = {Erlandson, Sarah C and Wang, Jialu and Jiang, Haoran and Osei-Owusu, James and Rockman, Howard A and Kruse, Andrew C},
title = {Engineering and Characterization of a Long-Half-Life Relaxin Receptor RXFP1 Agonist},
journal = {Molecular Pharmaceutics},
year = {2024},
doi = {10.1021/acs.molpharmaceut.4c00368}
}
EUVIMED